ETFs tracking the performance of weight-loss drugs have largely underperformed since launching in late 2023.
Our daily email brings you smart and engaging news and analysis on the biggest stories in business and finance. For free.
Interest in options among both professional and self-directed investors is surging, and new 0TDE ETFs are gaining popularity.